Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Fuchs Endothelial Corneal Dystrophy: early-phase trial registry

2 of 4 indexed Fuchs Endothelial Corneal Dystrophy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 2 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Fuchs Endothelial Corneal Dystrophy: 4 US clinical trials tracked, 2 recruiting.

Fuchs Endothelial Corneal Dystrophy is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Trefoil Therapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition fuchs-endothelial-corneal-dystrophy

OPEN 2 | RECR 50% | LATE 1 | EARLY 3 | RANK #4115 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Fuchs Endothelial Cornea (th…50%
Open-enrollment share among volume-matched conditions near Fuchs Endothelial Corneal Dystrophy

Fuchs Endothelial Corneal Dystrophy lists 2 open slots (50% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fuchs Endothelial Corneal Dystrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fuchs Endothelial Corneal Dystrophy is recruiting above its size-band peers.

    2 of 4 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Fuchs Endothelial Corneal Dystrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Vehicle (placebo) Other
1 trials
TTHX1114(NM141) Drug
1 trials
Visine Dry Eye Relief eye drops Drug
1 trials
N-acetyl cysteine (NAC) 20% solution Drug
1 trials
N-acetyl cysteine (NAC) 10% solution Drug
1 trials
DT-168 Drug
1 trials
Ripasudil Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Fuchs Endothelial Corneal Dystrophy trials. A trial with sites in several states counts in each.

New York 2 trials
Nebraska 2 trials
Michigan 2 trials
Massachusetts 2 trials
Indiana 2 trials
Florida 2 trials
California 2 trials
South Dakota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fuchs Endothelial Corneal Dystrophy page

4 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Fuchs Endothelial Corneal Dystrophy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Trefoil Therapeutics sponsors the most Fuchs Endothelial Corneal Dystrophy trials on record, review their full trial history before evaluating a specific study. See Trefoil Therapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fuchs Endothelial Corneal Dystrophy condition card totals 4 registered trials; most-linked intervention Vehicle (placebo); top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.